Sotera Health Company – Consensus ‘buy’ rating and 30.1% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Sotera Health Company with ticker code (SHC) have now 5 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 23 and 16 suggesting an average Analsyt target price of $19.00. Given that the stocks previous close was at $14.60 this indicates there is a potential upside of 30.1%. Also worth taking note is the 50 day moving average now sits at $16.49 while the 200 day moving average is $13.37. The market cap for the company is 4.12B. The current stock price for Targa Resources Corp. is currently 14.57 USD

The potential market cap would be $5,356,792,828 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of 3.52 and a 6.11% return on assets.

Sotera Health Company is a provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. The Company operates through three segments: Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. The Nordion segment is a provider of Cobalt-60 (Co-60) used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and materials industries, as well as in the treatment of cancer. In addition, it is a global provider of gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Shaftesbury Capital PLC appoints Madeleine Cosgrave as Non-executive Director, bringing extensive property sector experience to the Board.
    Shaftesbury Capital PLC acquires James Street property in Covent Garden for £75.1 million, presenting asset management opportunities and rental growth potential.

      Search

      Search